Interestingly, a recent study found that FJX1-specific peptides can inhibit the proliferation of high FJX1 expression cancer cells and may serve as a potential immunotherapy for NPC patients (22). The gene discussed is FJX1; the disease is nasopharyngeal carcinoma.